Published in “Nature” – Article about our Company and BNCT

The international science journal “Nature” published in its special edition “Radiology in Japan” (March 21^st, 2024, Volume 627 no. 8004) the article “Japan pioneers a new cancer radiation treatment”.

The advertorial describes our drug (generic name: Borofalan ¹⁰B) used in BNCT (Boron Neutron Capture Therapy) based on an interview with the following 3 persons:

Dr. Koji Ono (Kansai BNCT Medical Center at Osaka Medical and Pharmaceutical University)
Dr. Hiroshi Igaki (National Cancer Center Hospital in Tokyo)
Mr. Koki Uehara (Stella Pharma Corporation)

Not only the characteristics of BNCT and its principle are explained, but the reader also learns about the clinical evidence in Japan and the development of the neutron irradiation device that made the country to play a leading role in this field. The drug development of borofalan, used for BNCT, and the worldwide expansion are also depicted.

We believe this article will help to promote the recognition of BNCT among influential researchers, medical institutions, and global pharmaceutical companies. Please find the article following this link: Japan pioneers a new cancer radiation treatment (nature.com)

Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma Paper published: Clinical trial about Boron Neutron Capture Therapy for recurrent breast cancer